Skip to main content

PHR · "PHARMENA" SPÓŁKA AKCYJNA · Financials

3.0600 PLN +0.0000 (+0.00%) At close · Oct 2
Market Cap
34.42M PLN
Shares
11.14M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Browse captured authority reports and their original financial labels

Revenue
299K 0%
FY2023 Revenue FY2020–FY2023
Net Income
28.94M +1943.4%
FY2023 Net Income FY2020–FY2023
Gross Margin
-0.33% -30.8pp
FY2023 Gross Margin FY2020–FY2023
Operating Margin
11016.39% +12370.9pp
FY2023 Operating Margin FY2020–FY2023
Operating Cash Flow
33.03M +1715.9%
FY2023 Operating Cash Flow FY2020–FY2023

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2023 FY2022 FY2021 FY2020
PLN 299K 299K 15.21M 9.93M
PLN 300K 208K 7.38M 4.85M
PLN -1000 91K 7.83M 5.09M
PLN 3.59M 3.23M 4.68M 3.98M
PLN 32.94M -4.05M -3.98M -6.01M
PLN 577K 904K 474K 264K
PLN 32.93M -4.95M -4.46M -6.27M
PLN 5.91M 204K 182K 686K
PLN 28.94M -1.57M -4.59M -6.89M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current lease liabilities 2023-12-31 PLN 67,000 ESEF Annual Report filed 2024-02-29
Noncurrent lease liabilities 2023-12-31 PLN 114,000 ESEF Annual Report filed 2024-02-29
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.